SKOV3 ovarian carcinoma cells have functional estrogen receptor but are growth-resistant to estrogen and antiestrogens

被引:69
作者
Hua, WH
Christianson, T
Rougeot, C
Rochefort, H
Clinton, GM
机构
[1] OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201
[2] OREGON HLTH SCI UNIV,DEPT MOLEC & MED GENET,PORTLAND,OR 97201
[3] U148 INSERM,F-34090 MONTPELLIER,FRANCE
关键词
D O I
10.1016/0960-0760(95)00187-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Estrogen receptor positive ovarian cancer is often refractile to antiestrogen therapy. Here we describe the SKOV3 human ovarian carcinoma cell line as an in vitro model for estrogen and antiestrogen resistant ovarian cancer. While SKOV3 cells expressed estrogen receptor (ER) mRNA and protein at a similar level as the estrogen responsive T47D breast carcinoma cell line, their growth was not responsive to estradiol (E(2)) and was not inhibited by the antiestrogens OH-tamoxifen and ICI 164,384. The ER in SKOV3 cells was normal with respect to apparent K-d for binding with E(2), E(2) regulation of a transiently transfected ERE driven reporter gene, and E(2) stimulation of expression of the early growth response genes c-myc and c-fos. However, the SKOV3 cells exhibited no expression of the progesterone receptor gene (PR) even after addition of E(2), and the protein products of the estrogen responsive genes HER-2/neu and cathepsin D were expressed at constitutive levels that were not regulated by E(2). Therefore, estrogen resistance in these cells may be a result of constitutive expression and loss of E(2) regulation of selected growth regulatory gene products rather than a defect in estrogen activation of ER as a transcriptional regulator.
引用
收藏
页码:279 / 289
页数:11
相关论文
共 46 条
[1]   HORMONAL PALLIATION OF CHEMORESISTANT OVARIAN-CANCER - 3 CONSECUTIVE PHASE-II TRIALS OF THE MID-ATLANTIC ONCOLOGY PROGRAM [J].
AHLGREN, JD ;
ELLISON, NM ;
GOTTLIEB, RJ ;
LALUNA, F ;
LOKICH, JJ ;
SINCLAIR, PR ;
UENO, W ;
WAMPLER, GL ;
YEUNG, KY ;
ALT, D ;
FRYER, JG .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (10) :1957-1968
[2]  
Ausubel F. M., 1989, CURRENT PROTOCOLS MO, V1
[3]   ESTROGEN-DEPENDENT, TAMOXIFEN-RESISTANT TUMORIGENIC GROWTH OF MCF-7 CELLS TRANSFECTED WITH HER2/NEU [J].
BENZ, CC ;
SCOTT, GK ;
SARUP, JC ;
JOHNSON, RM ;
TRIPATHY, D ;
CORONADO, E ;
SHEPARD, HM ;
OSBORNE, CK .
BREAST CANCER RESEARCH AND TREATMENT, 1992, 24 (02) :85-95
[4]   SEQUENCE OF THE MURINE AND HUMAN CELLULAR MYC ONCOGENES AND 2 MODES OF MYC TRANSCRIPTION RESULTING FROM CHROMOSOME-TRANSLOCATION IN B-LYMPHOID TUMORS [J].
BERNARD, O ;
CORY, S ;
GERONDAKIS, S ;
WEBB, E ;
ADAMS, JM .
EMBO JOURNAL, 1983, 2 (12) :2375-2383
[5]   ESTROGENS AND GROWTH-FACTORS INDUCE THE MESSENGER-RNA OF THE 52K-PRO-CATHEPSIN-D SECRETED BY BREAST-CANCER CELLS [J].
CAVAILLES, V ;
AUGEREAU, P ;
GARCIA, M ;
ROCHEFORT, H .
NUCLEIC ACIDS RESEARCH, 1988, 16 (05) :1903-1919
[6]  
CHIEN CH, 1994, MOL CELL ENDOCRINOL, V99, P11
[7]  
CURRAN T, 1987, ONCOGENE, V2, P79
[8]  
DATI C, 1990, ONCOGENE, V5, P1001
[9]   ESTROGENIC REGULATION OF GROWTH AND POLYPEPTIDE GROWTH-FACTOR SECRETION IN HUMAN-BREAST CARCINOMA [J].
DICKSON, RB ;
LIPPMAN, ME .
ENDOCRINE REVIEWS, 1987, 8 (01) :29-43
[10]   ESTRADIOL STIMULATES CELL-GROWTH AND SECRETION OF PROCATHEPSIN-D AND A 120-KILODALTON PROTEIN IN THE HUMAN OVARIAN-CANCER CELL-LINE BG-1 [J].
GALTIERDEREURE, F ;
CAPONY, F ;
MAUDELONDE, T ;
ROCHEFORT, H .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 75 (06) :1497-1502